WEST LAFAYETTE, Ind., April 10, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that four posters will be presented by Endocyte scientists at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, April 18-22, 2015.
IF the market headed north, not wishful as for $23. However, the RED death looks to be upon most of us and Insmed suffers accordingly. frickin' market lacks direction. Thought it would wait until Friday. Just one day.
jad - OK so the Germany person(s) works with France too. Are we not trialing in Japan (yet)? Won't we need a marketing/sales partner in the near future? Just thinking "ahead". thx for posting your thoughts as always!
Medical Director (there are 2 jobs in Germany and one in the UK) SO, why just
Germany (and UK) and not Australia or any other country where trials are being run?
Responsible for developing and executing the Medical Affairs strategic plan for the Insmed product portfolio in Germany
•Key Opinion Leader (KOL) mapping and development of KOL deployment plans
•Manage the German Medical Science Liaisons • Delivery of medical education plans and activities such as local advisory boards / round tables / one-on-one meetings / presence at local country congresses
•Delivery of local scientific publications and communications
•Support for clinical development and local phase IV initiatives, including the risk management plans agreed with EMA
•Develop in conjunction with Medical EU medical tools and manage Investigator Initiated Clinical Trials (IIT´s) in Germany
•Management of the named patient sales/ compassionate supply program, prior to approval in Germany
•Provide medical and scientific expertise and leadership for the Commercial organization
• Managing the medical input into Market Access documentation like the AMNOG dossiers and others
•Approval of all Medical Affairs activities and medical-marketing materials, including assistance in translation into local languages
•Ensure local compliance and delivery of medical governance
I would suspect this wasn't a hard sell AND those who bought the 10M (and 1.5M) are not looking to "flip" these for a $1/shr gain.
well, we are KNOCKING on the $22.75 (which would be another high) but with low volume. If that breaks, look out $23.
One would suspect that the book runners and/or the co-managers of the $20.65 ($223M) recent offering would at least chime in with a PT on where Insmed is headed in the next 12 months. The quickness of getting this 11.5M share offering completed tells (me) that the demand was there with minimal discounting. So what gives?
Interesting connection to Merck:
"Dr. Mozley has over 25 years of experience using radiopharmaceuticals to diagnose and treat diseases. He is a board-certified physician in nuclear medicine. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan. From 2001 to 2012, Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck & Co. While at Merck & Co., he served as senior imaging lead across therapeutic areas for multi-center trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and co-chaired a technical committee on quantitative imaging for the Radiological Society of North America. He has contributed to the publication of over 100 research reports in the literature on imaging.
Dr. Mozley received his B.S. at the College of William & Mary, Williamsburg, VA, his M.D. from the Brody School of Medicine at East Carolina University, and trained at the University of Pennsylvania in Philadelphia."
Most perfect timing would be Citigroup, Leerink, Wainwright, UBS,or Cowen Upgrades or PT raises soon. That will propel us to $25 maybe even this week. We shall see.
"For most investors, the lack of sales growth is telling enough. Some need to be shown in a more convincing manner. When Contrave from Orexigen (NASDAQ:OREX) launched, Qsymia was one of two new anti-obesity drugs. It enjoyed a 48% market share. In the last 24 weeks, that share has eroded to just 29%. Qsymia has lost 19 points in 24 weeks. Belviq from Arena (NASDAQ:ARNA) has lost 13 points. Meanwhile, Contrave has gone from a 0% share to 31%."
The trend about 2 weeks ago was setting 52 wk highs almost daily. The overall market looks GREEN today so far. Insmed should soon trade again over the $22 range.
Hey KVN, (Big Island) if you have the time drive all the way down to where the road stops (west of live flow) there will be an arch over the water (which you are NOT to walk on hmmmmm). It is a great way to see all the flows over the past 5-30 years and new life too. good luck and enjoy (Kona is cool too)
I remember last year when Will was added to Qure's BOD and I watched the PPS 9around $10-$11 at the time). Well today QURE is over $33. Hope he has more than one horse shoe in his arsenal. LOL
Tom, I know what they were assigned (along with Leerink) but why Citigroup and not Piper Jaffray or Cowen. They are a new "player" with Insmed. Not complaining but wondering why they showed up out of "nowhere".
Citigroup? WHY are they here now? In any case, twice the offering or about $41/shr (over)
Of course it may be inaccurate but it was a positive "spin". most people/investors have no clue as to all the medicinal potential and diseases that are being addressed. I think you (smile) are a rare breed in BIO that has taken the time and more so has the ability to decipher what is really occurring. If we all had that, Endocyte would never have fallen 65-70% on May 2nd. The perception in the market is FAILURE and lost cause. Just happened to MEIP 10 days ago with just one trial/indication out of many still to be reported. Seems unfair (to me). But bottom line is Endocyte has a significant chance of success with its Foliate Receptor process with EC1456 and that story needs to get out there.